Alnylam Partners With Roche To Develop And Commercialize Zilebesiran, Alnylam's Investigational RNAi Therapeutic For The Treatment Of Hypertension
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals has partnered with Roche to develop and commercialize Zilebesiran, Alnylam's investigational RNAi therapeutic for hypertension treatment. Alnylam will receive an upfront cash payment of $310 million and is eligible for development, regulatory, and sales milestones, potentially valuing the deal at up to $2.8 billion. The companies will share profits and losses equally in the US, and Alnylam will receive royalties on net sales outside the US.
July 24, 2023 | 5:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam's partnership with Roche for the development and commercialization of Zilebesiran could significantly boost its revenues, given the potential deal value of up to $2.8 billion.
The partnership with Roche, a major pharmaceutical company, could significantly boost Alnylam's revenues and profitability, especially considering the potential deal value of up to $2.8 billion. This could positively impact Alnylam's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Roche's partnership with Alnylam to develop and commercialize Zilebesiran could enhance its product portfolio and potentially increase its revenues.
The partnership with Alnylam allows Roche to expand its product portfolio with a promising therapeutic for hypertension. This could potentially increase Roche's revenues and positively impact its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100